NLS GSK

The global, randomized, double-blind placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa, and Latin America. The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints being the prevention of severe […]

Tobias Bäckström, GSK’s new Medical Director, will be reporting to both Ebbe Englev, Cluster Medical Director and Niclas Källbom Karlsson, CEO of GSK Sweden, and he will be a part of the Swedish board of directors. “I look very much forward to working at GSK. GSK has exciting research and many novel interesting pharmaceuticals underway,” […]

Swedish Orphan Biovitrum has announced that Birgitte Volck, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases. Birgitte will work through a six month notice period before leaving Sobi. “We thank Birgitte […]

GlaxoSmithKline plans to take its ebola vaccine candidate to clinical trials and test it in Great Britain, Gambia and Mali. A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, states GSK, as part of a series of safety trials of potential vaccines aimed […]

Santaris Pharma A/S have announced that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines.  Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform […]